Published in Med Decis Making on December 06, 2011
Accounting for biases when linking empirical studies and simulation models. Med Decis Making (2012) 0.77
Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med (2000) 19.56
The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA (2002) 15.59
Human papillomavirus and cervical cancer. Lancet (2007) 12.47
Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J Natl Cancer Inst (2001) 6.36
Human papillomavirus testing in the prevention of cervical cancer. J Natl Cancer Inst (2011) 4.59
Research designs for studies evaluating the effectiveness of change and improvement strategies. Qual Saf Health Care (2003) 4.46
ACOG Practice Bulletin no. 109: Cervical cytology screening. Obstet Gynecol (2009) 4.27
Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. Am J Obstet Gynecol (2003) 3.55
ASCUS-LSIL Triage Study. Design, methods and characteristics of trial participants. Acta Cytol (2000) 3.26
Number of cervical biopsies and sensitivity of colposcopy. Obstet Gynecol (2006) 3.08
Chapter 2: Natural history of anogenital human papillomavirus infection and neoplasia. J Natl Cancer Inst Monogr (2003) 2.94
A randomized trial on the management of low-grade squamous intraepithelial lesion cytology interpretations. Am J Obstet Gynecol (2003) 2.45
Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance. JAMA (2002) 2.29
Colposcopically directed biopsy, random cervical biopsy, and endocervical curettage in the diagnosis of cervical intraepithelial neoplasia II or worse. Am J Obstet Gynecol (2004) 2.16
Findings to date from the ASCUS-LSIL Triage Study (ALTS). Arch Pathol Lab Med (2003) 1.97
Effects of age and human papilloma viral load on colposcopy triage: data from the randomized Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesion Triage Study (ALTS). J Natl Cancer Inst (2002) 1.68
Cost-effectiveness analysis based on the atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesion Triage Study (ALTS). J Natl Cancer Inst (2006) 1.58
Triage of women with equivocal or low-grade cervical cytology results: a meta-analysis of the HPV test positivity rate. J Cell Mol Med (2009) 1.48
Visual appearance of the uterine cervix: correlation with human papillomavirus detection and type. Am J Obstet Gynecol (2007) 1.23
The design of controlled experiments in the evaluation of non-therapeutic interventions. J Chronic Dis (1982) 1.15
ACOG Practice Bulletin No. 99: management of abnormal cervical cytology and histology. Obstet Gynecol (2008) 1.14
Age-specific prevalence of HPV genotypes in cervical cytology samples with equivocal or low-grade lesions. Br J Cancer (2009) 1.08
Experimental versus observational data in the economic evaluation of pharmaceuticals. Med Decis Making (1998) 0.89
Cost-effectiveness of enoxaparin versus warfarin prophylaxis against deep-vein thrombosis after total hip replacement. CMAJ (1994) 0.87
The confidence profile method: a Bayesian method for assessing health technologies. Oper Res (1989) 0.86
The colposcopic impression. Is it influenced by the colposcopist's knowledge of the findings on the referral Papanicolaou smear? J Reprod Med (2001) 0.80
Exorcising protocol-induced spirits: making the clinical trial relevant for economics. Med Decis Making (1997) 0.77
The relevance of searching for effects under a clinical-trial lamppost: a key issue. Med Decis Making (1996) 0.77
Human papillomavirus and cervical cancer. Lancet (2007) 12.47
Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst (2013) 8.75
TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A (2013) 6.88
The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst (2005) 6.03
Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol (2011) 5.59
American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin (2012) 5.58
2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Obstet Gynecol (2013) 5.40
Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials. Lancet Oncol (2015) 4.84
The carcinogenicity of human papillomavirus types reflects viral evolution. Virology (2005) 4.72
Human papillomavirus testing in the prevention of cervical cancer. J Natl Cancer Inst (2011) 4.59
Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine (2008) 4.31
Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection. J Natl Cancer Inst (2010) 3.95
Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst (2011) 3.92
Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology (2004) 3.85
Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica. J Infect Dis (2005) 3.84
Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States. J Natl Cancer Inst (2009) 3.77
Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening. Obstet Gynecol (2004) 3.67
Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer (2009) 3.64
A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. J Infect Dis (2007) 3.59
Comparisons of HPV DNA detection by MY09/11 PCR methods. J Med Virol (2002) 3.53
American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol (2012) 3.51
A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica. J Infect Dis (2005) 3.46
Human papillomavirus infection with multiple types: pattern of coinfection and risk of cervical disease. J Infect Dis (2011) 3.44
Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl Cancer Inst (2008) 3.32
Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica. Vaccine (2008) 3.17
Multiple human papillomavirus genotype infections in cervical cancer progression in the study to understand cervical cancer early endpoints and determinants. Int J Cancer (2009) 3.15
American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. J Low Genit Tract Dis (2012) 3.15
Number of cervical biopsies and sensitivity of colposcopy. Obstet Gynecol (2006) 3.08
Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst (2003) 3.08
2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis (2013) 3.06
The expanded use of HPV testing in gynecologic practice per ASCCP-guided management requires the use of well-validated assays. Am J Clin Pathol (2007) 2.91
Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial. Lancet Oncol (2011) 2.85
American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin (2007) 2.81
Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infections. J Natl Cancer Inst (2010) 2.81
Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2. Obstet Gynecol (2009) 2.74
Prospective follow-up suggests similar risk of subsequent cervical intraepithelial neoplasia grade 2 or 3 among women with cervical intraepithelial neoplasia grade 1 or negative colposcopy and directed biopsy. Am J Obstet Gynecol (2003) 2.71
Short term persistence of human papillomavirus and risk of cervical precancer and cancer: population based cohort study. BMJ (2009) 2.68
Cervical cancer prevention: new tools and old barriers. Cancer (2010) 2.68
Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: a community-based randomized clinical trial in Guanacaste, Costa Rica. Cancer Discov (2011) 2.66
Special commentary: patient safety and the next generation of HPV DNA tests. Am J Clin Pathol (2010) 2.65
Performance of high-risk human papillomavirus DNA testing as a primary screen for cervical cancer: a pooled analysis of individual patient data from 17 population-based studies from China. Lancet Oncol (2010) 2.61
The relationship of community biopsy-diagnosed cervical intraepithelial neoplasia grade 2 to the quality control pathology-reviewed diagnoses: an ALTS report. Am J Clin Pathol (2007) 2.52
Human papillomavirus genotype specificity of hybrid capture 2. J Clin Microbiol (2008) 2.51
Chapter 5: Updating the natural history of HPV and anogenital cancer. Vaccine (2006) 2.51
Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities. J Natl Cancer Inst (2005) 2.47
Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more. Obstet Gynecol (2004) 2.36
Relationships of human papillomavirus type, qualitative viral load, and age with cytologic abnormality. Cancer Res (2006) 2.33
Description of a seven-year prospective study of human papillomavirus infection and cervical neoplasia among 10000 women in Guanacaste, Costa Rica,. Rev Panam Salud Publica (2004) 2.33
CIN2 is a much less reproducible and less valid diagnosis than CIN3: results from a histological review of population-based cervical samples. Int J Gynecol Pathol (2007) 2.27
Comparison of linear array and line blot assay for detection of human papillomavirus and diagnosis of cervical precancer and cancer in the atypical squamous cell of undetermined significance and low-grade squamous intraepithelial lesion triage study. J Clin Microbiol (2007) 2.27
Restricted cross-reactivity of hybrid capture 2 with nononcogenic human papillomavirus types. Cancer Epidemiol Biomarkers Prev (2002) 2.24
Persistence of type-specific human papillomavirus infection and increased long-term risk of cervical cancer. J Natl Cancer Inst (2011) 2.18
Benchmarking CIN 3+ risk as the basis for incorporating HPV and Pap cotesting into cervical screening and management guidelines. J Low Genit Tract Dis (2013) 2.18
Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial. Cancer Prev Res (Phila) (2013) 2.17
Adding a test for human papillomavirus DNA to cervical-cancer screening. N Engl J Med (2003) 2.16
Epidemiology of human papillomavirus infection in men, cancers other than cervical and benign conditions. Vaccine (2008) 2.13
Utility of methylation markers in cervical cancer early detection: appraisal of the state-of-the-science. Gynecol Oncol (2008) 2.08
Hierarchy of resistance to cervical neoplasia mediated by combinations of killer immunoglobulin-like receptor and human leukocyte antigen loci. J Exp Med (2005) 2.06
High load for most high risk human papillomavirus genotypes is associated with prevalent cervical cancer precursors but only HPV16 load predicts the development of incident disease. Int J Cancer (2007) 2.06
Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica. PLoS One (2013) 2.03
Interobserver agreement in the assessment of components of colposcopic grading. Obstet Gynecol (2008) 1.96
The oral cavity contains abundant known and novel human papillomaviruses from the Betapapillomavirus and Gammapapillomavirus genera. J Infect Dis (2011) 1.87
Pooled analysis of a self-sampling HPV DNA Test as a cervical cancer primary screening method. J Natl Cancer Inst (2012) 1.86
Chapter 7: Achievements and limitations of cervical cytology screening. Vaccine (2006) 1.86
Colposcopy at a crossroads. Am J Obstet Gynecol (2006) 1.84
A prospective study of high-grade cervical neoplasia risk among human papillomavirus-infected women. J Natl Cancer Inst (2002) 1.83
A population-based prospective study of carcinogenic human papillomavirus variant lineages, viral persistence, and cervical neoplasia. Cancer Res (2010) 1.82
Age-related changes of the cervix influence human papillomavirus type distribution. Cancer Res (2006) 1.82
Interlaboratory reliability of Hybrid Capture 2. Am J Clin Pathol (2004) 1.82
A long-term prospective study of type-specific human papillomavirus infection and risk of cervical neoplasia among 20,000 women in the Portland Kaiser Cohort Study. Cancer Epidemiol Biomarkers Prev (2011) 1.82
Evolution and taxonomic classification of human papillomavirus 16 (HPV16)-related variant genomes: HPV31, HPV33, HPV35, HPV52, HPV58 and HPV67. PLoS One (2011) 1.80
A comparison between real-time polymerase chain reaction and hybrid capture 2 for human papillomavirus DNA quantitation. Cancer Epidemiol Biomarkers Prev (2003) 1.80
Viral load of human papillomavirus and risk of CIN3 or cervical cancer. Lancet (2002) 1.78
Risk assessment to guide the prevention of cervical cancer. Am J Obstet Gynecol (2007) 1.74
Breast and cervical cancer screening utilization among Hispanic women living near the United States-Mexico border. J Womens Health (Larchmt) (2011) 1.74
Impact of human papillomavirus vaccination on cervical cytology screening, colposcopy, and treatment. Am J Epidemiol (2013) 1.73
Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. J Low Genit Tract Dis (2015) 1.73
A comparison of a prototype PCR assay and hybrid capture 2 for detection of carcinogenic human papillomavirus DNA in women with equivocal or mildly abnormal papanicolaou smears. Am J Clin Pathol (2005) 1.73
Chapter 21: Modelling the impact of HPV vaccines on cervical cancer and screening programmes. Vaccine (2006) 1.71
Cost-effectiveness of HPV 16, 18 vaccination in Brazil. Vaccine (2007) 1.71
Stability of archived liquid-based cervical cytologic specimens. Cancer (2003) 1.70
Using biomarkers as objective standards in the diagnosis of cervical biopsies. Am J Surg Pathol (2010) 1.70
Human papillomavirus cofactors by disease progression and human papillomavirus types in the study to understand cervical cancer early endpoints and determinants. Cancer Epidemiol Biomarkers Prev (2009) 1.70
Predicting absolute risk of CIN3 during post-colposcopic follow-up: results from the ASCUS-LSIL Triage Study (ALTS). Am J Obstet Gynecol (2006) 1.69
Effects of age and human papilloma viral load on colposcopy triage: data from the randomized Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesion Triage Study (ALTS). J Natl Cancer Inst (2002) 1.68